Agenus to Unveil Phase 2 Botensilimab Melanoma Data at ASCO and Partner with BAP Pharma
Agenus will present first Phase 2 data for botensilimab alone or with balstilimab in advanced cutaneous melanoma refractory to anti–PD-(L)1 ± CTLA-4 at the 2026 ASCO Annual Meeting May 29–June 2 in Chicago. The company also named BAP Pharma as exclusive global partner to expand BOT+BAL access programs.
1. ASCO Presentation Schedule
Agenus will present four abstracts at the 2026 ASCO Annual Meeting in Chicago from May 29 to June 2, including the first Phase 2 clinical data for botensilimab alone or in combination with balstilimab in patients with advanced cutaneous melanoma refractory or resistant to anti–PD-(L)1 therapy, with or without prior CTLA-4 inhibition. Additional posters include an AI foundation model–based biomarker analysis in solid tumors and two trials-in-progress updates in colorectal cancer.
2. Global Access Partnership
The company appointed BAP Pharma as its exclusive global partner to manage BOT+BAL access programs, centralizing early and expanded access pathways worldwide. This collaboration is designed to streamline patient enrollment in compassionate use initiatives and broaden the availability of both botensilimab and balstilimab immunotherapy combinations.